This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.
Subjects voluntarily joined this study, signed the informed consent form, and had good compliance；
18-75 yeas old；
Eastern Cooperative Oncology Group Performance Status (ECOG) score: 0-1;
Expected survival of more than 12 weeks；
Current concomitant presence of other malignancies within 5 years prior to the first dose；
At the time of initiating the study of treatment, the adverse reactions caused by previous anti-tumor treatments failed to recover to a CTCAE 5.0 score of grade 1 or below.
Patients who had received major surgical treatment within 4 weeks prior to the first study, had obvious traumatic injuries, or were expected to undergo major surgery during the study treatment period, or had long-term unhealed wounds or fractures.
Hyperactive or venous thrombosis events occurred within 6 months before the first administration;